DuPont de Nemours Earnings Call Transcripts
Fiscal Year 2026
-
Q3 organic sales grew 5%, EBITDA margin expanded 90 bps, and adjusted EPS rose 31%. FY26 guidance increased again, with productivity, healthcare, aerospace, and EV battery demand supporting results.
-
Second quarter results exceeded guidance with 4% organic sales growth, margin expansion, and strong free cash flow. Full-year guidance was raised, supported by robust performance in healthcare, industrial, and semiconductor markets, and a $250 million share repurchase was announced.
-
The meeting covered strong recent financial results, strategic portfolio actions, and ongoing focus on innovation and shareholder returns. All management proposals, including a reverse stock split and share reduction, were approved by shareholders.
-
First quarter 2026 results exceeded expectations with strong sales, margin expansion, and double-digit EPS growth. Guidance for the full year was raised, reflecting robust performance in healthcare, aerospace, and operational execution, while pricing actions offset input cost pressures.
Fiscal Year 2025
-
Fourth quarter and full-year 2025 results exceeded guidance, with strong margin and EPS growth driven by operational discipline and portfolio transformation. 2026 guidance calls for 3% organic sales growth, margin expansion, and robust free cash flow, with Healthcare and Water segments leading growth.
-
Third quarter results exceeded guidance with 7% sales growth and 6% operating EBITDA growth, driven by strong performance in healthcare, water, and electronics. Full-year guidance was raised, capital allocation actions were announced, and the CUNY separation was completed, strengthening the balance sheet.
-
The company is executing a strategic transformation, focusing its portfolio on healthcare, water, and diversified industrials, targeting 3%-4% organic revenue CAGR and 8%-10% EPS growth by 2028. Operational excellence, disciplined capital allocation, and innovation are central to driving margin expansion and shareholder value.
-
Second quarter saw 2% organic sales growth and 8% higher operating EBITDA, led by electronics and healthcare/water, while construction remained weak. Full-year earnings guidance was raised, a $177M environmental settlement was announced, and the Cunity spinoff remains on track for November 1.
-
The meeting covered strong 2024 financial results, progress on the Qnity spin-off, and strategic focus on growth markets. All management proposals, including director elections and auditor ratification, were approved. Key governance and executive compensation topics were addressed.
-
First-quarter results exceeded expectations with strong growth in electronics, healthcare, and water, driving a 16% year-over-year increase in operating EBITDA and a 30% rise in adjusted EPS. The electronics spinoff (Qnity) remains on track, and tariff mitigation actions are expected to limit 2025 net cost impact to $60 million.
Fiscal Year 2024
-
Fourth quarter results showed 7% sales growth and 13% higher operating EBITDA, with strong performance in electronics and water. 2025 guidance calls for mid-single-digit organic growth, continued margin strength, and the electronics business spinoff by November 1.
-
Q3 2024 saw strong year-over-year growth in sales, EBITDA, and EPS, driven by volume recovery, operational excellence, and restructuring benefits. Guidance for full-year 2024 was raised, with continued momentum expected in electronics, water, and medical packaging, while business separations progress on schedule.
-
Second quarter results surpassed guidance with strong electronics recovery, margin expansion, and robust cash flow. Full-year guidance was raised, reflecting ongoing recovery, AI-driven growth, and the Donatelle acquisition. PFAS litigation risk is declining, and segment performance is improving.